Necrosis related HIF-1α expression predicts prognosis in patients with endometrioid endometrial carcinoma

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Seeber, Laura M S ^a   Horrée, Nicole ^a   van der Groep, Petra ^a   van der Wall, Elsken ^a   Verheijen, René H M ^a   van Diest, Paul J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; CDKN1B PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; SIGNAL PEPTIDE; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ENDOMETRIOID CARCINOMA; ENDOMETRIOID ENDOMETRIAL CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MYOMETRIUM; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR NECROSIS; ANOXIA; ENDOMETRIUM TUMOR; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; NECROSIS; PATHOLOGY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANOXIA; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; NECROSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 77953631157     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-307     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
2. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, Heintz AP, Ngan HY, Pecorelli S. Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006, 95(Suppl 1):S105-S143. 10.1016/S0020-7292(06)60031-3, 17161155.
3. Shimizu S, Eguchi Y, Kamiike W, Itoh Y, Hasegawa J, Yamabe K, Otsuki Y, Matsuda H, Tsujimoto Y. Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by Bcl-2 and Bcl-XL. Cancer Res 1996, 56:2161-2166.
4. Kurokawa T, Miyamoto M, Kato K, Cho Y, Kawarada Y, Hida Y, Shinohara T, Itoh T, Okushiba S, Kondo S, et al. Overexpression of hypoxia-inducible-factor 1alpha(HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer 2003, 89:1042-1047. 10.1038/sj.bjc.6601186, 2376949, 12966423.
5. Le QT, Denko NC, Giaccia AJ. Hypoxic gene expression and metastasis. Cancer Metastasis Rev 2004, 23:293-310. 10.1023/B:CANC.0000031768.89246.d7, 15197330.
6. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003, 97:1573-1581. 10.1002/cncr.11246, 12627523.
7. Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, Aarbodem Y, van Tinteren H, Harris AL, van Diest PJ, van der Wall E. Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol 2005, 58:172-177. 10.1136/jcp.2004.019885, 1770566, 15677538.
8. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002, 8:1831-1837.
9. Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?. Oncologist 2004, 9(Suppl 5):31-40. 10.1634/theoncologist.9-90005-31, 15591420.
10. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, Katschinski DM, Wenger RH. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 2003, 22:3213-3220. 10.1038/sj.onc.1206385, 12761491.
11. Greijer AE, de Jong MC, Scheffer GL, Shvarts A, van Diest PJ, van der Wall E. Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells. Cell Oncol 2005, 27:43-49.
12. Jiang BH, Semenza GL, Bauer C, Marti HH. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 1996, 271:C1172-C1180.
13. Greijer AE, van der Groep P, Kemming D, Shvarts A, Semenza GL, Meijer GA, van de Wiel MA, Belien JA, van Diest PJ, van der Wall E. Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 2005, 206:291-304. 10.1002/path.1778, 15906272.
14. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 1996, 271:32253-32259. 10.1074/jbc.271.50.32253, 8943284.
15. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999, 15:551-578. 10.1146/annurev.cellbio.15.1.551, 10611972.
16. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000, 88:1474-1480.
17. Ratcliffe PJ, O'Rourke JF, Maxwell PH, Pugh CW. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol 1998, 201:1153-1162.
18. Vaughan-Jones RD, Spitzer KW. Role of bicarbonate in the regulation of intracellular pH in the mammalian ventricular myocyte. Biochem Cell Biol 2002, 80:579-596. 10.1139/o02-157, 12440699.
19. Behrooz A, Ismail-Beigi F. Stimulation of Glucose Transport by Hypoxia: Signals and Mechanisms. News Physiol Sci 1999, 14:105-110.
20. Pedersen MW, Holm S, Lund EL, Hojgaard L, Kristjansen PE. Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro. Neoplasia 2001, 3:80-87. 10.1038/sj.neo.7900133, 1505028, 11326319.
21. Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, Harris AL. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001, 61:7992-7998.
22. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ, West CM. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001, 61:6394-6399.
23. Horree N, van Diest PJ, van der Groep P, Sie-Go DM, Heintz AP. Hypoxia and angiogenesis in endometrioid endometrial carcinogenesis. Cell Oncol 2007, 29:219-227.
24. Birner P, Gatterbauer B, Oberhuber G, Schindl M, Rossler K, Prodinger A, Budka H, Hainfellner JA. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 2001, 92:165-171. 10.1002/1097-0142(20010701)92:1<165::AID-CNCR1305>3.0.CO;2-F, 11443623.
25. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000, 60:4693-4696.
26. Osada R, Horiuchi A, Kikuchi N, Yoshida J, Hayashi A, Ota M, Katsuyama Y, Mellilo G, Konishi I. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum Pathol 2007, 38:1310-1320. 10.1016/j.humpath.2007.02.010, 17555795.
27. Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, Koukourakis MI. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 2002, 95:1055-1063. 10.1002/cncr.10774, 12209691.
28. Acs G, Xu X, Chu C, Acs P, Verma A. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 2004, 100:2376-2386. 10.1002/cncr.20244, 15160341.
29. Pansare V, Munkarah AR, Schimp V, Haitham AM, Saed GM, Morris RT, li-Fehmi R. Increased expression of hypoxia-inducible factor 1alpha in type I and type II endometrial carcinomas. Mod Pathol 2007, 20:35-43. 10.1038/modpathol.3800718, 17099695.
30. Pijnenborg JM, Wijnakker M, Hagelstein J, Delvoux B, Groothuis PG. Hypoxia contributes to development of recurrent endometrial carcinoma. Int J Gynecol Cancer 2007, 17:897-904. 10.1111/j.1525-1438.2007.00893.x, 17359291.
31. Green SL, Giaccia AJ. Tumor hypoxia and the cell cycle: implications for malignant progression and response to therapy. Cancer J Sci Am 1998, 4:218-223.
32. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000, 60:3689-3695.
33. Bamberger AM, Riethdorf L, Milde-Langosch K, Bamberger CM, Thuneke I, Erdmann I, Schulte HM, Loning T. Strongly reduced expression of the cell cycle inhibitor p27 in endometrial neoplasia. Virchows Arch 1999, 434:423-428. 10.1007/s004280050361, 10389625.
34. Schmitz MJ, Hendricks DT, Farley J, Taylor RR, Geradts J, Rose GS, Birrer MJ. p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma. Gynecol Oncol 2000, 77:439-445. 10.1006/gyno.2000.5814, 10831356.
35. Horree N, Gort E, van der Groep P, Heintz A, Vooijs M, van Diest P. Hypoxia-inducible factor 1alpha is essential for hypoxic p27 induction in endometrioid endometrial carcinoma. J Pathol 2008, 214:38-45. 10.1002/path.2244, 17985331.
36. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997, 3:227-230. 10.1038/nm0297-227, 9018244.
37. Masciullo V, Sgambato A, Pacilio C, Pucci B, Ferrandina G, Palazzo J, Carbone A, Cittadini A, Mancuso S, Scambia G, et al. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res 1999, 59:3790-3794.
38. Masciullo V, Susini T, Zamparelli A, Bovicelli A, Minimo C, Massi D, Taddei G, Maggiano N, De IP, Ceccaroni M, et al. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27(Kip1) in estrogen-related Endometrial adenocarcinomas. Clin Cancer Res 2003, 9:5332-5338.
39. Erkanli S, Kayaselcuk F, Kuscu E, Bagis T, Bolat F, Haberal A, Demirhan B. Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium. Int J Gynecol Cancer 2006, 16:1412-1418. 10.1111/j.1525-1438.2006.00541.x, 16803539.
40. van Diest PJ. No consent should be needed for using leftover body material for scientific purposes. For. BMJ 2002, 325:648-651. 10.1136/bmj.325.7365.648, 12242180.
41. Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, Gatter K, Millard P, Fuggle S, Harris AL. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 2002, 62:2493-2497.
42. Huang LW, Chao SL, Hwang JL, Chou YY. Down-regulation of p27 is associated with malignant transformation and aggressive phenotype of cervical neoplasms. Gynecol Oncol 2002, 85:524-528. 10.1006/gyno.2002.6666, 12051885.
43. Watanabe J, Sato H, Kanai T, Kamata Y, Jobo T, Hata H, Fujisawa T, Ohno E, Kameya T, Kuramoto H. Paradoxical expression of cell cycle inhibitor p27 in endometrioid adenocarcinoma of the uterine corpus - correlation with proliferation and clinicopathological parameters. Br J Cancer 2002, 87:81-85. 10.1038/sj.bjc.6600434, 2364278, 12085261.
44. Nycum LR, Smith LM, Farley JH, Kost ER, Method MW, Birrer MJ. The role of p27 in endometrial carcinoma. Gynecol Oncol 2001, 81:242-246. 10.1006/gyno.2001.6144, 11330957.
45. Scholten AN, Smit VT, Beerman H, van Putten WL, Creutzberg CL. Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. Cancer 2004, 100:764-772. 10.1002/cncr.20040, 14770433.
46. Lax SF, Kurman RJ, Pizer ES, Wu L, Ronnett BM. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am J Surg Pathol 2000, 24:1201-1208. 10.1097/00000478-200009000-00002, 10976693.
47. Sagae S, Saito T, Satoh M, Ikeda T, Kimura S, Mori M, Sato N, Kudo R. The reproducibility of a binary tumor grading system for uterine endometrial endometrioid carcinoma, compared with FIGO system and nuclear grading. Oncology 2004, 67:344-350. 10.1159/000082917, 15713989.